Skape Bio
Skape Bio will use protein design to create small therapeutic proteins, called minibinders, that modulate cell signaling by binding the integral membrane domains of key receptors (GPCRs, ion channels, and transporters). The project uses methods pioneered by David Baker’s laboratory at the University of Washington to create their new class of therapeutic proteins to modulate cell signaling.
Project summary
Purpose
To create a new class of therapeutic proteins to modulate cell signaling
Host university
University of Washington
Funding per year
DKK 6,5M
Duration
Three years
Expected outcome
Viable startup that can raise seed or Series A financing
Project leaders
See who heads the Skape Bio project on its mission to create a new class of therapeutic proteins to modulate cell signaling.
“De novo protein design is an exciting area and one that fits perfectly with our strategy to accelerate the commercialization of state-of-the-art technology.”
Markus Herrgård
Chief Technology Officer